Figure 2From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea In the overall population regardless of brain metastasis status, Kaplan-Meier estimates for (A) PFS by prior capecitabine; (B) OS by prior capecitabine; (C) PFS by hormone receptor (HR) status; (D) OS by HR status; (E) PFS by brain metastasis status in; (F) OS by brain metastasis status Back to article page